Indivior Pharmaceuticals, Inc. (INDV)
32.45
-1.17
(-3.48%)
USD |
NASDAQ |
Oct 16, 16:00
32.41
-0.04
(-0.12%)
After-Hours: 20:00
Indivior Pharmaceuticals Cash from Investing (Quarterly) : -7.942M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.942M |
| March 31, 2026 | -19.00M |
| December 31, 2025 | -22.46M |
| September 30, 2025 | -20.46M |
| June 30, 2025 | -18.68M |
| March 31, 2025 | -5.00M |
| December 31, 2024 | 8.101M |
| September 30, 2024 | 35.16M |
| June 30, 2024 | 0.9378M |
| March 31, 2024 | 25.00M |
| December 31, 2023 | 6.142M |
| September 30, 2023 | -0.3355M |
| June 30, 2023 | 26.29M |
| March 31, 2023 | -127.00M |
| December 31, 2022 | -6.687M |
| September 30, 2022 | -59.20M |
| June 30, 2022 | -17.40M |
| March 31, 2022 | -149.00M |
| December 31, 2021 | -2.004M |
| September 30, 2021 | 17.79M |
| June 30, 2021 | -31.23M |
| March 31, 2021 | 1.00M |
| December 31, 2020 | -2.046M |
| Date | Value |
|---|---|
| September 30, 2020 | -2.028M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 1.018M |
| September 30, 2019 | -1.002M |
| June 30, 2019 | -0.0132M |
| March 31, 2019 | -2.00M |
| December 31, 2018 | 19.03M |
| September 30, 2018 | -11.81M |
| June 30, 2018 | -17.73M |
| March 31, 2018 | 6.00M |
| December 31, 2017 | -4.684M |
| September 30, 2017 | -22.44M |
| June 30, 2017 | -8.00M |
| March 31, 2017 | -8.00M |
| December 31, 2016 | -13.25M |
| September 30, 2016 | -11.10M |
| June 30, 2016 | -8.989M |
| March 31, 2016 | -4.00M |
| December 31, 2015 | -15.33M |
| September 30, 2015 | -3.873M |
| June 30, 2015 | -12.00M |
| March 31, 2015 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 7.094M |
| Eli Lilly & Co. | -15.40B |
| Bristol Myers Squibb Co. | -1.614B |
| Liquidia Corp. | -12.24M |
| Harmony Biosciences Holdings, Inc. | -131.50M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 228.52M |
| Cash from Financing (Quarterly) | -172.64M |
| Free Cash Flow | -119.51M |
| Free Cash Flow Per Share (Quarterly) | 1.787 |
| Free Cash Flow to Equity (Quarterly) | 221.58M |
| Free Cash Flow to Firm (Quarterly) | 223.11M |
| Free Cash Flow Yield | -2.91% |